Anais Brasileiros De Dermatologia[JOURNAL]

Sun 200 papers

RSS

Comment on "The relationship of FricTest® responses with an urticaria activity score, urticaria control test and quality of life scales in patients with symptomatic dermographism".

Satapathy P, Mehta R, Sah R

An Bras Dermatol · 2026 · PMID 41544315 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗

BLyS/APRIL dual inhibition by telitacicept for refractory pemphigus vulgaris combined with hepatocellular cancer.

Chen W, Xu J, Zhang Y

An Bras Dermatol · 2026 · PMID 41544314 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗

Update on novel acne treatments: a narrative review focused on microbiome modulation and non-pharmacological approaches.

Burckhardt-Bravo V, Funes-Ferrada R, Valenzuela F

An Bras Dermatol · 2026 · PMID 41544313 · Full text

Acne vulgaris is a chronic inflammatory condition with multifactorial pathogenesis. Despite the availability of numerous treatment options, there remains a need for safe, well-tolerated, and microbiome-preserving therapi... Acne vulgaris is a chronic inflammatory condition with multifactorial pathogenesis. Despite the availability of numerous treatment options, there remains a need for safe, well-tolerated, and microbiome-preserving therapies. This narrative review explores recent advances in non-pharmacological acne treatments, focusing on various microbiome modulation strategies. It highlights emerging therapeutic modalities and their potential impact on clinical practice. Key findings from recent studies are summarized, providing insights for future research and practical applications in dermatology.

Free PDF PubMed ↗

Treatment of extensive oral leukoplakia with diode laser - Successful case report.

Tolentino ES, de Miranda FV, Santos TCD … +4 more , Ikeshoji LHS, Arioso LS, Santos PSDS, Cardoso CL

An Bras Dermatol · 2026 · PMID 41544312 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗

Hemorrhagiectatic carcinoma: an uncommon clinical presentation of cutaneous metastasis from pulmonary adenocarcinoma.

Lobos-Guede N, Hartmann D, Villarroel FC … +3 more , Concha PM, Silva-Hirschberg C, Barros MD

An Bras Dermatol · 2026 · PMID 41544311 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗

Novel sporadic c.2687G>T (p.Gly896Val) CYLD mutation in multiple trichoepitheliomas.

Atılan AU, Cetin N

An Bras Dermatol · 2026 · PMID 41544310 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗

Type IV pityriasis rubra pilaris treated with ixekizumab.

Ferreirinha A, João A, Brito Caldeira M

An Bras Dermatol · 2026 · PMID 41539158 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗

Rapid clinical response in refractory discoid lupus erythematosus treated with anifrolumab.

Ramos J, Leme H, Magarreiro-Silva A

An Bras Dermatol · 2026 · PMID 41539157 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗

Letter to the Editor regarding: "Pre-and post-analytical guidelines for the microscopic diagnosis of melanoma: recommendations from the Brazilian Society of Pathology".

Jabur da Cunha JA, Gomes Tarle R, Tassara Tavares G

An Bras Dermatol · 2026 · PMID 41518772 · Full text

Abstract loading — click title to view on PubMed.

Free PDF PubMed ↗

Lipedema: pathophysiological insights and therapeutic strategies - An update for dermatologists.

Dal'Forno-Dini T, Birck MS, Saalfeld RM … +2 more , Macedo CLD, Bagatin E

An Bras Dermatol · 2026 · PMID 41512532 · Full text

Lipedema is a chronic and progressive disorder characterized by disproportionate fat accumulation, mainly affecting the lower extremities of women, and commonly accompanied by sensations of heaviness, tenderness, and dis... Lipedema is a chronic and progressive disorder characterized by disproportionate fat accumulation, mainly affecting the lower extremities of women, and commonly accompanied by sensations of heaviness, tenderness, and discomfort. While its pathogenesis remains largely unknown, genetic, hormonal, and microvascular factors have been implicated. The condition often coexists with psychological distress, which significantly detracts from the quality of life of affected individuals. Diagnosis is primarily clinical, as no specific biomarkers or imaging modalities have been proven sufficiently reliable for identification. Proposed managements are controversial, although current treatment focuses on symptom management and disease control through conservative methods such as compression and non-invasive device therapies, specialized diets, and physical rehabilitation or surgical treatments. Psychological support is vital in addressing the emotional challenges of the condition. Despite recent advancements in the understanding and management of lipedema, there remains a critical need for further research to establish standardized diagnostic criteria and targeted therapeutic strategies for this debilitating condition.

Free PDF PubMed ↗

Frequency of HLA class I and II in an admixed Brazilian population with psoriasis.

Sampaio AL, Romana-Souza B, Monteiro H … +8 more , Nogueira JS, Secco DA, Santos GCD, Monte-Alto-Costa A, Cassia F, Carneiro S, Azulay-Abulafia L, Porto LC

An Bras Dermatol · 2026 · PMID 41512531 · Full text

BACKGROUND: Psoriasis is a chronic, immune-mediated disease with a significant genetic component. The HLA-C*06:02 allele is one of the most strongly associated with the disease, particularly influencing early onset and s... BACKGROUND: Psoriasis is a chronic, immune-mediated disease with a significant genetic component. The HLA-C*06:02 allele is one of the most strongly associated with the disease, particularly influencing early onset and severity. There are few current data on genetics in a Brazilian population with psoriasis. OBJECTIVE: This study aimed to investigate the genetic associations between human leucocyte antigen (HLA) alleles and psoriasis in a Brazilian admixed population. METHODS: We conducted HLA class I and II genotyping in 144 patients with psoriasis and compared the results with those of 720 controls. Additionally, we calculated the Psoriasis Area and Severity Index (PASI) and recorded whether the patient had current or previous systemic treatment for psoriasis and the age of disease onset. RESULTS: HLA-B*13:02g, B*15:01g, B*37:01g, B*38:01g, B*57:01g, B*57:02g, B*13:02g, C*01:02g, C*06:02g, C*12:03g, C*18:01g, DRB1*01:02g, DRB1*04:08g and DPB1*04:01g alleles were associated with an increased risk of psoriasis (after the Bonferroni correction factor, only the HLA-C*06:02 remained significant). And HLA-DRB1*15:03g conferred protection against psoriasis after Bonferroni correction. Alleles significantly associated with PASI score < 10 were A*34:02g (p = 0.037) and B*50:01g (p = 0.037), while the allele related to PASI > 10 was DRB1*01:01g (p = 0.049). When comparing the age of disease onset, the following alleles were significantly associated with early onset psoriasis (before 30 years of age): B*44:03g (p = 0.010) and C*07:02g (p = 0.022). STUDY LIMITATIONS: The sample size was small compared with other international publications, and the subgroup of patients with mild disease was less represented; however, the combination of analytical approaches (univariate tests, PCA, and correction for multiple comparisons) reinforces the robustness of the work. CONCLUSION: The present findings highlight the genetic complexity of psoriasis in a diverse population and suggest that it may not be directly linked to specific genetic factors. Further research is required to explore the environmental and genetic interactions that contribute to psoriasis pathogenesis.

Free PDF PubMed ↗

Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis.

Vieira ACP, Lins FC, Baquião AC

An Bras Dermatol · 2026 · PMID 41512530 · Full text

BACKGROUND: Cutaneous leishmaniasis (CL) affects up to 1.2 million people annually, mainly in resource-limited regions. Meglumine antimoniate, the standard treatment, is limited by systemic toxicity, injectable administr... BACKGROUND: Cutaneous leishmaniasis (CL) affects up to 1.2 million people annually, mainly in resource-limited regions. Meglumine antimoniate, the standard treatment, is limited by systemic toxicity, injectable administration, and increasing resistance. Miltefosine, an oral alternative, offers practical advantages, although comparative efficacy and safety data remain inconsistent. OBJECTIVE: To compare the efficacy and safety of miltefosine versus meglumine antimoniate for New World CL. METHODS: The authors systematically searched PubMed, Embase, Scopus, and the Cochrane Library for randomized controlled trials directly comparing miltefosine and meglumine antimoniate. Risk Ratios (RRs) with 95% Confidence Intervals (95% CIs) were calculated using random-effects models. Heterogeneity was assessed with the I² statistic. Risk of bias was evaluated using the Cochrane RoB-2 tool. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. RESULTS: Eight trials involving 898 patients (502 treated with miltefosine, 396 with meglumine antimoniate) were included. Miltefosine showed significantly higher cure rates at two months (RR = 0.83; 95% CI: 0.71-0.98; I = 0%). Differences at six months were not statistically significant. Gastrointestinal side effects were more frequent with miltefosine, whereas hepatic enzyme elevations, arthralgia (RR = 10.08; 95% CI: 2.36-43.12), and fever (RR = 2.98; 95% CI: 1.53-5.80) were more common with meglumine antimoniate. STUDY LIMITATIONS: High heterogeneity, short follow-up, small sample sizes, and interstudy variability may limit precision. CONCLUSION: Miltefosine shows superior early response and a safer systemic profile. However, the certainty of evidence, as assessed by GRADE, ranged from very low to high across outcomes, and long-term data remain limited, highlighting the need for further high-quality studies with extended follow-up.

Free PDF PubMed ↗